Journal
JOURNAL OF BIOMEDICAL SCIENCE
Volume 23, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12929-016-0289-5
Keywords
Mesenchymal stem cells; Human; Immunomodulation; Inflammation; Clinical trials; Autoimmune disease; Organ transplantation and rejection; Stem cell therapy
Categories
Funding
- NHRI [CS-105-PP-06]
- Taiwan Ministry of Science Technology [MOST-104-2321-B-400-021, MOST-104-2314-B-400-002]
- NHRI [CS-105-PP-06]
- Taiwan Ministry of Science Technology [MOST-104-2321-B-400-021, MOST-104-2314-B-400-002]
Ask authors/readers for more resources
Human mesenchymal stem cells (MSCs) are multilineage somatic progenitor/stem cells that have been shown to possess immunomodulatory properties in recent years. Initially met with much skepticism, MSC immunomodulation has now been well reproduced across tissue sources and species to be clinically relevant. This has opened up the use of these versatile cells for application as 3rd party/allogeneic use in cell replacement/tissue regeneration, as well as for immune-and inflammation-mediated disease entities. Most surprisingly, use of MSCs for in immune-/inflammation-mediated diseases appears to yield more efficacy than for regenerative medicine, since engraftment of the exogenous cell does not appear necessary. In this review, we focus on this non-traditional clinical use of a tissue-specific stem cell, and highlight important findings and trends in this exciting area of stem cell therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available